Evidence map›Paper›PMID 37256131›Full record

ArticleFrontiers in immunology2023

Adenoviral-vectored epigraph vaccine elicits robust, durable, and protective immunity against H3 influenza A virus in swine.

Erika Petro-Turnquist, Matthew Pekarek, Nicholas Jeanjaquet, Cedric Wooledge, David Steffen, Hiep Vu, Eric A Weaver

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Swine influenza A virus: challenges and novel vaccine strategies.Frontiers in cellular and infection microbiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Erika Petro-TurnquistNebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States.
Matthew PekarekNebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States.
Nicholas JeanjaquetNebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States.
Cedric WooledgeOffice of Research and Development, University of Nebraska-Lincoln, Lincoln, NE, United States.
David SteffenNebraska Veterinary Diagnostic Center, Lincoln, NE, United States.
Hiep VuNebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States.
Eric A WeaverNebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States.
University of Nebraska–Lincoln · US

Funding

Rapid Manufacturing of a Universal Flu Vaccine Using TMV-conjugated Centralized AntigensR01AI147109 · NIAID · UNIVERSITY OF NEBRASKA LINCOLN · PI MCCORMICK, ALISON ANNE, WEAVER, ERIC A · 2020 to 2024
$3.2M
Comparative Virology Research Training ProgramT32AI125207 · NIAID · UNIVERSITY OF NEBRASKA LINCOLN · PI WEAVER, ERIC A · 2016 to 2020
$844k
NIAID NIH HHS R01 AI147109NIAID NIH HHS T32 AI125207
6 · The paper itself

Abstract

Current methods of vaccination against swine Influenza A Virus (IAV-S) in pigs are infrequently updated, induce strain-specific responses, and have a limited duration of protection. Here, we characterize the onset and duration of adaptive immune responses after vaccination with an adenoviral-vectored Epigraph vaccine. In this longitudinal study we observed robust and durable antibody responses that remained above protective titers six months after vaccination. We further identified stable levels of antigen-specific T cell responses that remained detectable in the absence of antigen stimulation. Antibody isotyping revealed robust class switching from IgM to IgG induced by Epigraph vaccination, while the commercial comparator vaccine failed to induce strong antibody class switching. Swine were challenged six months after initial vaccination, and Epigraph-vaccinated animals demonstrated significant protection from microscopic lesion development in the trachea and lungs, reduced duration of viral shedding, lower presence of infectious virus and viral antigens in the lungs, and significant recall of antigen-specific T cell responses following challenge. The results obtained from this study are useful in determining the kinetics of adaptive immune responses after vaccination with adjuvanted whole inactivated virus vaccines compared to adenoviral vectored vaccines and contribute to the continued efforts of creating a universal IAV-S vaccine.

Indexed as

Influenza A virusInfluenza VaccinesOrthomyxoviridae InfectionsAdenoviridaeAnimalsLongitudinal StudiesLungSwineVaccines, InactivatedInfluenza VaccinesVaccines, Inactivatedadenoviral (Ad) vectordurationepigraphpathologyswine influenzatransmissionvaccine

Identifiers

PMID37256131
PMCPMC10225514
OpenAlexW4378783441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.